BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 24, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2016

View Archived Issues

Efficacy and safety of ribavirin-free DAA treatments in patients with severe renal impairment

Read More

AzurRx BioPharma and Mayoly Spindler launch phase II study of MS-1819-SD

Read More

EC grants orphan drug designation to Ra Pharmaceuticals' RA-101495

Read More

L807-mts demonstrates promising results in mouse model of Alzheimer's disease

Read More

Novel Zika virus infection model in immunocompetent neonatal C57Bl/6 mice

Read More

VH-298 is a novel potent and selective chemical probe of hypoxic signaling

Read More

Novel animal models presented at the Society for Neuroscience annual meeting

Read More

Nippon Boehringer Ingelheim and Astellas launch Micatrio combination tablets in Japan

Read More

PharmAkea extends collaboration with Celgene

Read More

Omeros patents PDE10A inhibitors

Read More

University of North Carolina at Chapel Hill discloses anticancer agents

Read More

Shanghai Fochon Pharmaceutical describes CDK4/cyclin D1 and CDK6/cyclin D1 inhibitors

Read More

Chinese scientists develop Nav1.7 channel blockers

Read More

Laboratorios del Dr. Esteve presents dual sigma1 and mu-opioid receptor ligands

Read More

UMC launches phase II program combining DCVax-L and pembrolizumab

Read More

Alzheimer's Association grant supports Proclara's development of NPT-088

Read More

Athenex to conduct phase Ib study of Oraxol in combination with ramucirumab

Read More

Apricus plans for Vitaros NDA resubmission next year

Read More

Medicure to acquire majority interest in Apicore

Read More

Novartis acquires Selexys Pharmaceuticals

Read More

Aska Pharmaceutical ready to launch Rifxima tablets in Japan

Read More

European Commission approves Trisenox for first-line treatment of low to intermediate risk APL

Read More

Boehringer Ingelheim launches idarucizumab as reversal agent for dabigatran in Japan

Read More

GSK submits NDA for closed triple combination therapy for COPD

Read More

Bristol-Myers Squibb launches elotuzumab in Japan

Read More

MSD K.K. launches elbasvir and grazoprevir in Japan

Read More

Bilanoa launched in Japan

Read More

Otsuka launches Iclusig in Japan

Read More

Laboratoris Sanifit reports clinical data on SNF-472

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 23, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing